|Quantity Discounts||1 - 2|
|3 - 4|
|5 - 6|
|7 - 9|
|10 - 9999|
False Claims Act Liability for Regulatory Noncompliance: An Update for Drug and Device Manufacturers
The Department of Justice’s interim final rule virtually doubles penalities for those that violate the False Claims Act.
How can you avoid liability under the FCA?
Anna Laakmann — Counsel, Greenberg Traurig — explains how regulatory noncompliance can form the basis of an FCA enforcement action by the government. She’ll highlight areas of regulatory risk and discuss key developments about the implied certification theory of FCA liability.
After listening to this session you will know:
Order today and remain in compliance with the interim final rule of the FCA.
Anna B. Laakmann, of Counsel at Greenberg Traurig, focuses her practice on litigation and regulatory matters for pharmaceutical, medical device, and life sciences companies. Before joining the firm, Anna was an associate professor at Lewis & Clark Law School, where she taught medical technology law, bioethics and public health law, intellectual property survey, patent law and policy and property. Anna has written and spoken extensively on the impact of civil litigation and government regulation on scientific research and the practice of medicine.
Copyright ©2018. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing